[1] P. Morice, A. Leary, C. Creutzberg, N. Abu-Rustum, E. Darai, Endometrial cancer, The Lancet 387(10023) (2016) 1094-1108.
[2] R. Angioli, F. Plotti, S. Capriglione, R. Montera, P. Damiani, R. Ricciardi, A. Aloisi, D. Luvero, E.V. Cafa, N. Dugo, M. Angelucci, P. Benedetti-Panici, The role of novel biomarker HE4 in endometrial cancer: a case control prospective study, Tumour Biol 34(1) (2013) 571-6.
[3] J.I. Sorosky, Endometrial cancer, Obstet Gynecol 120(2 Pt 1) (2012) 383-97.
[4] K.M. Doll, A.N. Winn, Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis, Am J Obstet Gynecol 221(4) (2019) 318 e1-318 e9.
[5]. W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, J. He, Cancer statistics in China, 2015, CA Cancer J Clin 66(2) (2016) 115-32.
[6] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J Clin 70(1) (2020) 7-30
[7] R.G. Moore, C.M. Miller, A.K. Brown, K. Robison, M. Steinhoff, G. Lambert-Messerlian, Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus, Int J Gynecol Cancer 21(7) (2011) 1185-90.
[8] K. Abbink, P.L. Zusterzeel, A.J. Geurts-Moespot, A.E.V. Herwaarden, J.M. Pijnenborg, F.C. Sweep, L.F. Massuger, HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients, Tumour Biol 40(2) (2018) 1010428318757103.
[9] J. Bian, X. Sun, B. Li, L. Ming, Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer, Technol Cancer Res Treat 16(4) (2017) 435-439.
[10] J.M. Escudero, J.M. Auge, X. Filella, A. Torne, J. Pahisa, R. Molina, Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases, Clin Chem 57(11) (2011) 1534-44.
[11] M. Li, L. Zhao, D. Shen, X. Li, J. Wang, L. Wei, Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma, Chin Med J (Engl) 127(8) (2014) 1459-63.
[12] A.C. Staff, J. Trovik, A.G. Eriksson, E. Wik, K.C. Wollert, T. Kempf, H.B. Salvesen, Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer, Clin Cancer Res 17(14) (2011) 4825-33.
[13] T. Kurihara, H. Mizunuma, M. Obara, K. Andoh, Y. Ibuki, T. Nishimura, Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma, Gynecol Oncol 69(3) (1998) 192-6.
[14] E. Baser, T. Gungor, C. Togrul, O. Turkoglu, S. Celen, Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers?, Eur J Gynaecol Oncol 35(5) (2014) 513-8.
[15] A. Gadducci, S. Cosio, A. Carpi, A. Nicolini, A.R. Genazzani, Serum tumor markers in the management of ovarian, endometrial and cervical cancer, Biomed Pharmacother 58(1) (2004) 24-38.
[16] T. Kaku, T. Kamura, T. Hirakawa, K. Sakai, S. Amada, H. Kobayashi, H. Nakano, Endometrial carcinoma associated with hyperplasia--immunohistochemical study of angiogenesis and p53 expression, Gynecol Oncol 72(1) (1999) 51-5.
[17] M. Modarres-Gilani, M. Vaezi, M. Shariat, N. Zamani, R. Nourizadeh, The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma, Cancer Biomark 20(2) (2017) 135-141.
[18] B. Patsner, G.W. Yim, Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012, Obstet Gynecol Sci 56(5) (2013) 281-8.
[19] M. Nikolaou, H.P. Kourea, V. Tzelepi, G. Adonakis, C.D. Scopa, V. Tsapanos, D. Kardamakis, C. Kalofonos, G. Decavalas, The prognostic role of preoperative serum CA 125 levels in patients with endometrial carcinoma, J BUON 19(1) (2014) 198-202.
[20] K.A. Williams, K.L. Terry, S.S. Tworoger, A.F. Vitonis, L.J. Titus, D.W. Cramer, Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival, PLoS One 9(2) (2014) e88334.
[21] B. Patsner, W.J. Mann, H. Cohen, M. Loesch, Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma, Am J Obstet Gynecol 158(2) (1988) 399-402.
[22] E. Bignotti, M. Ragnoli, L. Zanotti, S. Calza, M. Falchetti, S. Lonardi, S. Bergamelli, E. Bandiera, R.A. Tassi, C. Romani, P. Todeschini, F.E. Odicino, F. Facchetti, S. Pecorelli, A. Ravaggi, Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients, Br J Cancer 104(9) (2011) 1418-25.
[23] K. Abiko, T. Baba, M. Ogawa, Y. Mikami, T. Koyama, M. Mandai, I. Konishi, Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus, Pathol Int 60(1) (2010) 42-7.
[24] D.J. Brennan, A. Hackethal, A.M. Metcalf, J. Coward, K. Ferguson, M.K. Oehler, M.A. Quinn, M. Janda, Y. Leung, M. Freemantle, A. Group, P.M. Webb, A.B. Spurdle, A. Obermair, Serum HE4 as a prognostic marker in endometrial cancer--a population based study, Gynecol Oncol 132(1) (2014) 159-65.
[25] M. El-Bahrawy, Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract, Eur J Cancer 46(8) (2010) 1317-22.
[26] J.S. Su, Y.T. Chen, R.C. Wang, C.Y. Wu, S.W. Lee, T.Y. Lee, Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review, World J Gastroenterol 19(3) (2013) 321-7.
[27] A. Andren-Sandberg, Molecular biology of gallbladder cancer: potential clinical implications, N Am J Med Sci 4(10) (2012) 435-41.
[28] P. Letelier, P. Brebi, O. Tapia, J.C. Roa, DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer, Clin Epigenetics 4(1) (2012) 11.